Bexlosteride
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(4aS,10bR)-8-chloro-4-methyl-1,2,4a,5,6,10b-hexahydrobenzo[f]quinolin- | |
| Clinical data | |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| CAS Number |
202189-78-4  |
| ATC code | None |
| PubChem | CID 166562 |
| ChemSpider |
145762  |
| UNII |
36X732P4P0 |
| ChEMBL |
CHEMBL24955 |
| Chemical data | |
| Formula | C14H16ClNO |
| Molar mass | 249.73594 g/mol |
| |
| |
| (what is this?) (verify) | |
Bexlosteride (LY-191,704) is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride.[1][2] It is selective for the type I isoform of the enzyme.[1] It was never marketed.
Synthesis
Preparation of Bexlosteride:[3]
Notes
A QSAR model was developed (1993):[4]
See also
References
- 1 2 Chang, Chawnshang (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4.
- ↑ Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6.
- ↑ Astleford, B. A.; Audia, J. E.; Deeter, J.; Heath, P. C.; Janisse, S. K.; Kress, T. J.; Wepsiec, J. P.; Weigel, L. O. (1996). "Resolution of δ-Lactams Provides Access to Nonracemic Benzoquinolinones: The Synthesis of LY300502 and LY300503". The Journal of Organic Chemistry 61 (13): 4450–4454. doi:10.1021/jo9601425. PMID 11667351.
- ↑ Wikel, J. H.; Bemis, K. G.; Audia, J. E.; McQuaid, L. A.; Jones, C. D.; Pennington, P. A.; Lawhorn, D. E.; Hirsch, K. R.; Stamm, N. B. (1993). "QSAR study of benzoquinolinones as inhibitors of human type 1 5-α-reductase". Bioorganic & Medicinal Chemistry Letters 3 (6): 1157. doi:10.1016/S0960-894X(00)80306-6.
| ||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, September 05, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.